Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND

News SummaryMost relevantAll newsSector news 

Ligand Pharmaceuticals Inc. : SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ligand Pharmaceuticals Incorporated

05/17/2013 | 12:55pm US/Eastern

NEW YORK, May 17, 2013 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND), and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

To get more information, click here: http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/. There is no cost or obligation to you.

If you own common stock in Ligand Pharmaceuticals Incorporated and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP

React to this article
07/30 LIGAND PHARMACEUTICALS : Enters into Commercial License and Supply Agreement wit..
07/25 LIGAND PHARMACEUTICALS : Sets Release of Second Quarter Results
07/24 LIGAND PHARMACEUTICALS : Revolade® Recommended by CHMP for EU Approval to Treat ..
07/21 LIGAND PHARMACEUTICALS : Schedules Release of Second Quarter Results
07/16 LIGAND PHARMACEUTICALS : to Report Second Quarter Results on August 4th
06/25 LIGAND PHARMACEUTICALS : NASDAQ:LGND) a Hold: Cantor Fitzgerald (Irina Rivkind C..
06/24 LIGAND PHARMACEUTICALS : FDA Approves Promacta® for New Pediatric Chronic Immune..
06/24 LIGAND PHARMACEUTICALS : to Participate in 4 Upcoming Investor Conferences
06/22 LIGAND PHARMACEUTICALS : to Participate in 4 Upcoming Investor Conferences
06/21 LIGAND PHARMACEUTICALS : FDA OKs Promacta for New Pediatric Chronic Immune Throm..